WHO ICTRP trial
Fluorouracil / Epirubicin / Cyclophosphamide (FEC) followed by Docetaxel plus…
JPRN-UMIN000001077 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000001077 |
|---|---|
| Public title | Fluorouracil / Epirubicin / Cyclophosphamide (FEC) followed by Docetaxel plus Cyclophosphamide (TC) as adjuvant chemotherapy for node positive breast cancer |
| Scientific title | Fluorouracil / Epirubicin / Cyclophosphamide (FEC) followed by Docetaxel plus Cyclophosphamide (TC) as adjuvant chemotherapy for node positive breast cancer - Fluorouracil / Epirubicin / Cyclophosphamide (FEC) followed by Docetaxel plus Cyclophosphamide (TC) as adjuvant chemotherapy for node… |
| Primary sponsor | Kinki Multidisciplinary Breast Oncology Group |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | BreastCancer |
| Interventions | FEC followed by Docetaxel 75 mg/m2, IV, Day 1 Cyclophosphamide 600mg/m2, IV, Day 1 Every 21 days for 4 cycles |
| Registration date | Mar 13, 2008 |
| Target size | 35 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: